contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


attana-biosensors-to-characterize-immune-response-to-bacterial-diseases

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Attana conducts research and development of pharmaceuticals. The company specialises in vitro characterization of molecular interactions, which is used for analysis in the development of new pharmaceuticals. The company's patented solutions are mainly used in the study of different binding properties and macrostructures in cells, proteins, viruses, and bacteria. Operations are found mainly within the Nordic countries and Europe. The company was established in 2002 is based in Stockholm.

Attana

Within the research project "Advanced Materials for Personalized Medicine and Diagnostics (https://lnu.se/en/research/research-projects/project-advanced-materials-for-personal-medicine-and-diagnostics...

<div class="abstract">Within the research project "Advanced Materials for Personalized Medicine and Diagnostics &nbsp;(<a href="https://lnu.se/en/research/research-projects/project-advanced-materials-for-personal-medicine-and-diagnostics/">https://lnu.se/en/research/research-projects/project-advanced-materials-for-personal-medicine-and-diagnostics/</a>)(AMPMeD)" at the Linnaeus University, the sub-projects, "Enhanced bacterial infection diagnosis" lead by Dr. Sofia Somajo is now initiating test of Borrelia infected individuals. Sera and dry blood samples will be tested according to Attanas immunity profiles concept.</div>The AmPMeD project started previously this year and includes the entire chain from sampling, via analysis to reporting. The project's participants gather expertise from the commercial and public sectors as well as researchers and developers. Within the sub-project "Enhanced bacterial infection diagnostics" the last months has focused on combining information on different variants of Borrelia geographically presence, market potential and available commercial antigens suitable for diagnostic assays.Everything is now set, and the experiments will be initiated in the beginning of January, when all necessary reagents and samples are available. The experimental set up will contain antigens from Borrelia afzelii and Borrelia garinii, both belonging to the Borrelia burgdorferi senso latu complex. In Sweden and other initially relevant European markets, the infection is mainly caused by these species.The experiments will initially be performed using serum samples focusing on compatibility with existing assays, but the focus will be to add the quantitative dry blood spot (qDBS sampling cards) to facilitate home sampling at the end of the project. The latter is important since early and correct treatment of the infection is important for a fast and complete recovery for the individual. Home sampling enables convenient early testing and Attana's immunity profiles will ensure fast and relevant data regarding the immune response over time.For more information about Borrelia infection and the scientific part of the project, contact: sofia.somajo@lnu.seFor more information about immunity profile and biosensors, contact: teodor.aastrup@attana.com

Stay up to date with our newsletter